Patricia Pozo-Rosich

Aug 19, 2024 | nature.com | Patricia Pozo-Rosich |Stephen D Silberstein

AbstractOnabotulinumtoxinA (BTX-A) was first linked to beneficial effects in migraine 25 years ago and was approved by the FDA for preventive treatment of chronic migraine in 2010. The treatment has since had a major impact on the well-being of people with chronic migraine.

Oct 5, 2023 | headachejournal.onlinelibrary.wiley.com | Richard Lipton |Patricia Pozo-Rosich |Serena L Orr |Michael Reed

ASC-12 12-item Allodynia Symptom Checklist CaMEO Chronic Migraine Epidemiology and Outcomes CI confidence interval EF Emotional Function EM episodic migraine GAD-7 seven-item Generalized Anxiety Disorder assessment HIT-6 Headache Impact Test-6 HRQoL health-related quality of life ICHD-3 International Classification of Headache Disorders, third edition MHD monthly headache day MSQ Migraine-Specific Quality-of-Life Questionnaire, version 2.1 PHQ-9 Patient Health Questionnaire-9 RFP Role...

Jul 26, 2023 | thelancet.com | Patricia Pozo-Rosich |Universitat Autònoma |Jessica Ailani |Messoud Ashina

Summary In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine. We did this randomised, double-blind, placebo-controlled, phase 3 trial at 142 clinical research sites across the USA, the UK, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, South Korea, Poland, Russia, Spain, Sweden, and Taiwan.

Feb 20, 2023 | n.neurology.org | Richard Lipton |Universitat Autònoma |Patricia Pozo-Rosich

AbstractBackground and Objectives The oral calcitonin gene–related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine. Methods In this phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial (ADVANCE), adults with 4–14 migraine days per month received atogepant (10, 30, or 60 mg) once daily or placebo.